# DREAMM 6 (NCT03544281)

> To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

No report yet. It can be ordered.

- Drugs tested: belantamab mafodotin plus lenalidomide plus dexamethasone; belantamab mafodotin plus bortezomib plus dexamethasone
- Indication: relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03544281
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin; Lenalidomide; Dexamethasone; Bortezomib
- Enrollment: 153
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A
- Primary outcome: Number of Participants With DLTs, Treatment B
- Primary outcome: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants With Worst-Case Amount of Increase From Baseline Value in Corrected QT Interval Using Fredericia's Formula (QTcF)
- Primary outcome: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Primary outcome: Number of Participants With Worst-case Change Post-baseline in Hematology Parameters
- Primary outcome: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Primary outcome: Number of Participants With Worst-case Change Post-baseline in Clinical Chemistry Parameters
- Primary outcome: Number of Participants With Worst-case Change Post Baseline Urinalysis Results: Occult Blood and Protein
- Primary outcome: Change From Baseline in Urine Potential of Hydrogen (pH)
- Primary outcome: Change From Baseline in Urine Specific Gravity
- Primary outcome: Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
- Primary outcome: Change From Baseline in Vital Signs : Pulse Rate
- Primary outcome: Change From Baseline in Vital Signs : Temperature
- Primary outcome: Overall Response Rate (ORR) as Defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma (MM)

## Indexed commentary on DREAMM 6 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dreamm-6-nct03544281

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03544281", "email": "<work email>"}; the inbox owner confirms by the emailed link.